On September 9th, the U.S. House of Representatives passed the BIOSECURE Act and now heads to the Senate. The bill would prohibit contracting with certain Chinese biotechnology companies deemed potential national security risks, specifically BGI, MGI, Complete Genomics, WuXi AppTec and WuXi Biologics.   The legislation gives U.S. drugmakers contracting with these companies until 2032 to terminate contracts and find new service providers.   If passed, concerns remain that the bill could furth...